One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease

Z. Tulassay, Andrzej Kryszewski, Petr Dite, Dariusz Kleczkowski, Janusz Rudzinski, Zbigniew Bartuzi, Göran Hasselgren, Ann Larkö, Michael Wrangstadh

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: Proton pump inhibitor (PPI) monotherapy is commonly continued for 3 weeks after Helicobacter pylori eradication with PPI-based triple therapy regimens to ensure duodenal ulcer (DU) healing. This randomized, double-blind, multicentre study evaluated whether only 1 week of triple therapy with the new PPI esomeprazole was sufficient to ensure high rates of ulcer healing and H. pylori eradication. Methods: A total of 446 H. pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg (n = 222) or omeprazole 20 mg (n = 224) in combination with amoxicillin 1 g and clarithromycin 500 mg for 1 week (EAC and OAC, respectively). Patients in the OAC group then received 3 weeks' monotherapy with omeprazole 20 mg once daily; those treated with EAC received placebo. Ulcer healing was assessed by endoscopy on completion of therapy and H. pylori status was assessed by 13C-urea breath testing and histology 4-6 weeks later. Results: Ulcer healing rates (95% CI) for intention-to-treat and per-protocol populations were: EAC + placebo 91% (87-95%) and 94% (90-97%); OAC + omeprazole 92% (88-95%) and 96% (92-98%). Corresponding H. pylori eradication rates were: EAC + placebo 86% (81-90%) and 89% (843-93%); OAC + omeprazole 88% (83-92%) and 90% (85-93%). Both eradication regimens were well tolerated, and patient compliance was high. Conclusions: A 1 -week regimen of esomeprazole-based triple therapy is sufficient for DU healing and H. pylori eradication in patients with DU disease.

Original languageEnglish
Pages (from-to)1457-1465
Number of pages9
JournalEuropean Journal of Gastroenterology and Hepatology
Volume13
Issue number12
DOIs
Publication statusPublished - 2001

Fingerprint

Esomeprazole
Duodenal Diseases
Duodenal Ulcer
Helicobacter pylori
Omeprazole
Proton Pump Inhibitors
Ulcer
Placebos
Therapeutics
Clarithromycin
Amoxicillin
Patient Compliance
Double-Blind Method
Endoscopy
Multicenter Studies
Urea
Histology
Population

Keywords

  • Antibiotics
  • Duodenal ulcers
  • Eradication therapy
  • Helicobacter pylori
  • Proton pump inhibitors
  • Triple therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. / Tulassay, Z.; Kryszewski, Andrzej; Dite, Petr; Kleczkowski, Dariusz; Rudzinski, Janusz; Bartuzi, Zbigniew; Hasselgren, Göran; Larkö, Ann; Wrangstadh, Michael.

In: European Journal of Gastroenterology and Hepatology, Vol. 13, No. 12, 2001, p. 1457-1465.

Research output: Contribution to journalArticle

Tulassay, Z. ; Kryszewski, Andrzej ; Dite, Petr ; Kleczkowski, Dariusz ; Rudzinski, Janusz ; Bartuzi, Zbigniew ; Hasselgren, Göran ; Larkö, Ann ; Wrangstadh, Michael. / One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. In: European Journal of Gastroenterology and Hepatology. 2001 ; Vol. 13, No. 12. pp. 1457-1465.
@article{cd7b23e88f894936bf9b4c45c1e37b84,
title = "One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease",
abstract = "Background: Proton pump inhibitor (PPI) monotherapy is commonly continued for 3 weeks after Helicobacter pylori eradication with PPI-based triple therapy regimens to ensure duodenal ulcer (DU) healing. This randomized, double-blind, multicentre study evaluated whether only 1 week of triple therapy with the new PPI esomeprazole was sufficient to ensure high rates of ulcer healing and H. pylori eradication. Methods: A total of 446 H. pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg (n = 222) or omeprazole 20 mg (n = 224) in combination with amoxicillin 1 g and clarithromycin 500 mg for 1 week (EAC and OAC, respectively). Patients in the OAC group then received 3 weeks' monotherapy with omeprazole 20 mg once daily; those treated with EAC received placebo. Ulcer healing was assessed by endoscopy on completion of therapy and H. pylori status was assessed by 13C-urea breath testing and histology 4-6 weeks later. Results: Ulcer healing rates (95{\%} CI) for intention-to-treat and per-protocol populations were: EAC + placebo 91{\%} (87-95{\%}) and 94{\%} (90-97{\%}); OAC + omeprazole 92{\%} (88-95{\%}) and 96{\%} (92-98{\%}). Corresponding H. pylori eradication rates were: EAC + placebo 86{\%} (81-90{\%}) and 89{\%} (843-93{\%}); OAC + omeprazole 88{\%} (83-92{\%}) and 90{\%} (85-93{\%}). Both eradication regimens were well tolerated, and patient compliance was high. Conclusions: A 1 -week regimen of esomeprazole-based triple therapy is sufficient for DU healing and H. pylori eradication in patients with DU disease.",
keywords = "Antibiotics, Duodenal ulcers, Eradication therapy, Helicobacter pylori, Proton pump inhibitors, Triple therapy",
author = "Z. Tulassay and Andrzej Kryszewski and Petr Dite and Dariusz Kleczkowski and Janusz Rudzinski and Zbigniew Bartuzi and G{\"o}ran Hasselgren and Ann Lark{\"o} and Michael Wrangstadh",
year = "2001",
doi = "10.1097/00042737-200112000-00009",
language = "English",
volume = "13",
pages = "1457--1465",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease

AU - Tulassay, Z.

AU - Kryszewski, Andrzej

AU - Dite, Petr

AU - Kleczkowski, Dariusz

AU - Rudzinski, Janusz

AU - Bartuzi, Zbigniew

AU - Hasselgren, Göran

AU - Larkö, Ann

AU - Wrangstadh, Michael

PY - 2001

Y1 - 2001

N2 - Background: Proton pump inhibitor (PPI) monotherapy is commonly continued for 3 weeks after Helicobacter pylori eradication with PPI-based triple therapy regimens to ensure duodenal ulcer (DU) healing. This randomized, double-blind, multicentre study evaluated whether only 1 week of triple therapy with the new PPI esomeprazole was sufficient to ensure high rates of ulcer healing and H. pylori eradication. Methods: A total of 446 H. pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg (n = 222) or omeprazole 20 mg (n = 224) in combination with amoxicillin 1 g and clarithromycin 500 mg for 1 week (EAC and OAC, respectively). Patients in the OAC group then received 3 weeks' monotherapy with omeprazole 20 mg once daily; those treated with EAC received placebo. Ulcer healing was assessed by endoscopy on completion of therapy and H. pylori status was assessed by 13C-urea breath testing and histology 4-6 weeks later. Results: Ulcer healing rates (95% CI) for intention-to-treat and per-protocol populations were: EAC + placebo 91% (87-95%) and 94% (90-97%); OAC + omeprazole 92% (88-95%) and 96% (92-98%). Corresponding H. pylori eradication rates were: EAC + placebo 86% (81-90%) and 89% (843-93%); OAC + omeprazole 88% (83-92%) and 90% (85-93%). Both eradication regimens were well tolerated, and patient compliance was high. Conclusions: A 1 -week regimen of esomeprazole-based triple therapy is sufficient for DU healing and H. pylori eradication in patients with DU disease.

AB - Background: Proton pump inhibitor (PPI) monotherapy is commonly continued for 3 weeks after Helicobacter pylori eradication with PPI-based triple therapy regimens to ensure duodenal ulcer (DU) healing. This randomized, double-blind, multicentre study evaluated whether only 1 week of triple therapy with the new PPI esomeprazole was sufficient to ensure high rates of ulcer healing and H. pylori eradication. Methods: A total of 446 H. pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg (n = 222) or omeprazole 20 mg (n = 224) in combination with amoxicillin 1 g and clarithromycin 500 mg for 1 week (EAC and OAC, respectively). Patients in the OAC group then received 3 weeks' monotherapy with omeprazole 20 mg once daily; those treated with EAC received placebo. Ulcer healing was assessed by endoscopy on completion of therapy and H. pylori status was assessed by 13C-urea breath testing and histology 4-6 weeks later. Results: Ulcer healing rates (95% CI) for intention-to-treat and per-protocol populations were: EAC + placebo 91% (87-95%) and 94% (90-97%); OAC + omeprazole 92% (88-95%) and 96% (92-98%). Corresponding H. pylori eradication rates were: EAC + placebo 86% (81-90%) and 89% (843-93%); OAC + omeprazole 88% (83-92%) and 90% (85-93%). Both eradication regimens were well tolerated, and patient compliance was high. Conclusions: A 1 -week regimen of esomeprazole-based triple therapy is sufficient for DU healing and H. pylori eradication in patients with DU disease.

KW - Antibiotics

KW - Duodenal ulcers

KW - Eradication therapy

KW - Helicobacter pylori

KW - Proton pump inhibitors

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=0035217178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217178&partnerID=8YFLogxK

U2 - 10.1097/00042737-200112000-00009

DO - 10.1097/00042737-200112000-00009

M3 - Article

C2 - 11742194

AN - SCOPUS:0035217178

VL - 13

SP - 1457

EP - 1465

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 12

ER -